Skip Navigation LinksHome > November 2011 - Volume 111 - Issue 11 > Safety Concerns Over an Osteoporosis Drug
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000407287.40125.eb
Drug Watch

Safety Concerns Over an Osteoporosis Drug

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* The label for the osteoporosis drug Reclast has been revised to strengthen the warning concerning the risk of acute renal failure, a rare adverse effect.

* Prior to administering the drug, nurses should assess patients for risk factors for acute renal failure: decreased creatinine clearance, older age, and dehydration.

© 2011 Lippincott Williams & Wilkins, Inc.

Login